# Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA) - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/clinical-development-programs-for-drugs-devices-and-biological-products-for-the-treatment-of-rheumatoid-arthritis-ra/c6678a1b-ae2a-4f48-92c5-5c50a3029502

> FDA guidance document: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). Issue date: February 17, 1999. Get complete insights and analysis.

---

## Details

- Title: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 1999-02-17
- Last Changed: 2025-01-31
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-1996-D-0004">FDA-1996-D-0004</a>

## Related Documents

- [Possible Dioxin/PCB Contamination of Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/possible-dioxinpcb-contamination-of-drug-and-biological-products/0b7513ce-1394-47e9-950d-c555f4b6845a)
- [Consumer-Directed Broadcast Advertisements:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/consumer-directed-broadcast-advertisements-guidance-for-industry/91a74b38-7614-49df-9da1-d64c111be3db)
- [Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies](https://www.globalkeysolutions.net/guidances/guidance-document/developing-medical-imaging-drug-and-biological-products-part-3-design-analysis-and-interpretation-of-clinical-studies/560bad6d-d575-4a09-84e7-a396f541a476)